Where to buy Toripalimab and how much it costs

Toripalimab (Toripalimab) is a selective recombinant humanized monoclonal antibody against programmed death protein 1 (PD-1), developed by Shanghai Junshi Bioscience Co. Ltd (Junshi Bioscience Co. Ltd) . Toripalimab binds to PD-1 and blocks the interaction with its ligand. The binding of toripalimab to PD-1 is mainly attributed to the heavy chain of the former and the FG loop of the latter.

Toripalimab received conditional approval in China in December 2018 for the treatment of melanoma (second-line) and it has also received approval in for the treatment of nasopharyngeal carcinoma (first- and third-line) and urothelial cancer (second-line) in 2021. In addition, the U.S. Food and Drug Administration (FDA) granted toripalimab several orphan drug designations. Toripalimab exhibits major anti-tumor effects in tumors such as melanoma, lung cancer, gastrointestinal tumors, hepatobiliary and pancreatic tumors, neuroendocrine tumors, nasopharyngeal carcinoma and urothelial carcinoma.

It showed promising anti-tumor efficacy and long-term survival benefit in Chinese melanoma patients, while the combination of axitinib and toripalimab showed impressive results in metastatic mucosal melanoma. As a checkpoint inhibitor, toripalimab was generally well tolerated among enrolled patients. Direct comparisons between toripalimab and other drugs are not possible in most cases due to different study populations. However, the introduction of toripalimab may provide a valuable option for future oncology treatment decisions.